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Welcome!
Walking through Washington, D.C., it’s
easy to be drawn in by the kaleidoscope of unique
sights and sounds that make up each neighborhood. From the quiet shores of the Potomac in
the George Washington University’s (GW) Foggy
Bottom home to the bustle of Capitol Hill, the
communities we serve are as diverse as the residents that call D.C., Maryland, and Virginia home.
But the historic charm of our neighborhoods often masks the difficult truth – health disparities
and economic inequality continue to disproportionately affect some communities, often manifesting in a higher cancer burden, less access to
care, and worse health outcomes.
At the GW Cancer Center, we believe we have
a responsibility to work toward health equity.
Whether at the patient’s bedside or crunching
data in a lab, connection with the communities we
serve forms the foundation of everything we do.
That’s why we chose “re:connect” as the theme of
this issue — it’s part of our mission to listen, understand, and address many of the problems that
are unique to our region so that, ultimately, we
see progress against cancer at a population level.
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This year we welcomed Carla J. Berg, PhD,
MBA, as our associate center director for population sciences and policy. Berg’s strong background in multilevel determinants of health
bolsters our efforts to address prevention and
strengthens our connections with our colleagues
in public health and policy.
In the city that has among the highest percentages of individuals who identify as lesbian, gay, bisexual, transgender, queer, or intersex (LGBTQI),
the GW Cancer Center is ensuring residents are
heard through the LGBTQI Research Community
Advisory Board, which comprises more than a
dozen representatives from the metro Washington, D.C., area and local organizations. Connection also comes by reaching out to our community
to provide access to critical services and innovative trials. This year, the GW Mammovan, a selfcontained mobile breast imaging clinic, celebrated nearly 25 years of addressing regional gaps
in access to mammography services. At the GW
Cancer Center, patients can also connect with the
latest clinical trials, like new studies for patients
with cutaneous squamous cell carcinoma.
Connection can also mean metrics and data. By
measuring the impact of Medicaid policy changes
on patient care, we can better communicate with
policymakers and inform future structural efforts.
We’re collecting data on a biological level through
our AIDS and Cancer Specimen Resource, which
was recently awarded a prestigious five-year grant
from the National Institutes of Health to connect
and meet the needs of researchers nationwide
studying HIV-associated cancers.
Connection also continues internally by building bridges between population scientists, clinicians, and basic/translational scientists; breaking
down silos to create a community of excellence
where all those with the intent to serve others
and lessen the alarming cancer disparities in the
greater Washington, D.C., area are welcome.
As we open a new decade of innovation and
progress here at the GW Cancer Center, I am excited to see what the future holds. I hope you’ll
join me as we share responsibility for, and renew
our commitment to, health equity in every corner
of our enterprise and maximize our impact upon
the community we serve.
EDUARDO M. SOTOMAYOR, MD
Dr. Cyrus Katzen Family Director of the
George Washington University (GW) Cancer Center
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IN BRIEF

Lighting a SPARC
The George Washington University (GW) Summer Program Advancing
Research on Cancer (GW-SPARC) welcomed its second cohort of undergraduates from universities across the United States over summer break. The
program is open to undergraduate students from groups underrepresented
in the biomedical sciences and provides participants with a hands-on approach to cancer research. This year, GW-SPARC expanded to include any
undergraduate students in GW Cancer Center laboratories.
Through the program, students have the opportunity to work in GW Cancer
Center labs alongside mentors and gain experience conducting research. At
the end of the summer, students presented at a poster session open to undergraduates in labs across GW, including in chemistry and engineering.
“The process of discovery, innovation, and the intellectual freedom that
you get in [research] when you are passionate about science excites me,” said
Adriana Hernandez, a participant in the GW-SPARC program from the University of Puerto Rico at Ponce. “Having this experience has made me more
interested in continuing in cancer research.”

HANDS-ON APPROACH
Through the GW-SPARC program,
students have the opportunity
to work in GW Cancer Center
labs alongside mentors and gain
experience conducting research.

The GW-SPARC program is open to undergraduate students
from groups underrepresented in the biomedical sciences.

GW Researcher Investigates
Role of BRCA1 in DNA Repair
A research team led by Yanfen
Hu, PhD, professor of anatomy and
cell biology at the George Washington University (GW) School of
Medicine and Health Sciences and a
member of the GW Cancer Center,
is studying the role of the tumor suppressor BRCA1 in the homologous
recombination pathway, the body’s
mechanism for DNA double-strand
repair.
“Our work seeks to validate a previously unrecognized role of BRCA1
in licensing the commitment step in
homologous recombination [a type
of ‘high-quality’ repair machinery
that faithfully repairs DNA doublestrand breaks,]” said Hu. “This chal-
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lenges the current view of BRCA1
as merely a scaffolding protein.”
Based on preliminary data, the
team hypothesizes that BRCA1
modifications are part of a process
that senses the damage, but manages to time the fix to that window
of high-quality repair. Interestingly, both nuclease recruitment
and inhibition are part of the
timing control strategy. They also
propose that the repair activity is
particularly important for genetic
integrity of luminal genes in luminal cells of breast tissue, where
many BRCA1-associated tumors
originate.

IN BRIEF

NEW PROGRAM
DIRECTOR
George Kim, MD, (left)
recently joined the GW
Cancer Center as director of its Gastrointestinal Cancers Program.

GW Graduate
Student Receives
Grant from BUCK
Cancer Foundation
Kimberly Cabe, FNP-BC, a graduate student majoring in integrative

George Kim, MD, New Multidisciplinary
Gastrointestinal Cancers Program Lead
Accomplished medical oncologist George Kim, MD, recently
joined the GW Cancer Center as director of its Gastrointestinal Cancers Program.
The program brings together medical, surgical and radiation
oncologists, interventional radiologists, gastroenterologists, genetic
counselors, nutritionists, and other supportive care professionals. The
multidisciplinary model provides patients with access to multiple specialties working together as a team and improves outcomes
for patients.
Kim, who specializes in colorectal, pancreatic, liver, and gastric
esophageal cancers, most recently provided medical oncology services at 21st Century Oncology in Florida. He previously worked at the
Mayo Clinic in Jacksonville, Florida, and the National Cancer Institute in
Bethesda, Maryland.
Kim also has an extensive research background, including serving
as the principal investigator for clinical trials studying the effectiveness
of different treatments for gastrointestinal cancers.

medicine at the George Washington
University School of Medicine and
Health Sciences, received the BUCK
Cancer Foundation 2019 Pay A BUCK
Forward educational grant
for $4,000.
A family nurse practitioner, Cabe
has a dedication to patient-centered
care that, combined with her continuing education through multiple
graduate programs, made her stand
out from other applicants.
The Pay A BUCK Forward educational grant program offers pay-back
grants to students pursuing a degree
in integrative medicine or a complementary cancer treatment. The grant
provides funds to selected students
with the expectation that once they
graduate and are fully employed, they
will pay back
the grant as
PAYING IT FORWARD
a percentage
Kimberly Cabe, FNP-BC,
of their salary.
(left), received the BUCK

Cancer Foundation 2019
Pay A BUCK Forward
educational grant.

The George Washington University Cancer Center

3

IN BRIEF

A clinical trial for patients
with high-risk cutaneous
squamous cell carcinoma
lead by Vishal A. Patel,
MD, is estimated to
enroll more than 400
participants worldwide.

GW Cancer Center First Site for Clinical Trial in
Patients with Cutaneous Squamous Cell Carcinoma

Under the leadership of Vishal
A. Patel, MD, director of the Cutaneous Oncology Program at the George
Washington University (GW) Cancer
Center, the center was selected as
the first global site of a clinical trial
for patients with high-risk cutaneous
squamous cell carcinoma.
The study, sponsored by biotechnology company Regeneron in collaboration with multinational pharmaceutical firm Sanofi, will compare

GLOBAL SITE OF
CARCINOMA CLINICAL TRIALS
The Cutaneous Oncology Program at
the GW Cancer Center has been selected as the first global site of a clinical trial for patients with high-risk
cutaneous squamous cell carcinoma.
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disease-free survival of patients treated with adjuvant cemiplimab with
disease-free survival of those treated
with placebo after surgery and radiation therapy.
“This selection highlights the commitment of the GW Cancer Center
to invest in the development of a
premier multidisciplinary cutaneous
oncology program in the District of
Columbia,” said Patel, who leads the
study. The randomized, placebocontrolled, double-blind Phase III
trial is intended to investigate cemiplimab’s safety and effectiveness
in preventing recurrence and metastasis in high-risk cutaneous squamous cell carcinoma. The study is
estimated to enroll more than 400
participants worldwide.

Cemiplimab was approved by the
U.S. Food and Drug Administration in
September 2018 to treat patients with
metastatic cutaneous squamous cell
carcinoma or locally advanced cutaneous squamous cell carcinoma who
are not candidates for curative surgery
or curative radiation. The immunotherapy treatment was the first treatment approved and available in the
United States for this type of advanced
skin cancer.
“By conducting this trial, we hope to
understand whether this approach can
help the patient’s own immune system control the skin cancer and keep
it from coming back,” said Mitchell
Smith, MD, PhD, associate center director for clinical investigations at the GW
Cancer Center. n

IN BRIEF

NEW ASSOCIATE DIRECTOR
Carla Berg, PhD, MBA, is the GW
Cancer Center’s new associate
center director for population sciences and policy.

Carla Berg, PhD, MBA, Joins GW Cancer
Center to lead Population Sciences and Policy

Carla Berg, PhD, MBA, brings years
of expertise to the George Washington University (GW) Cancer Center in
the role of associate center director
for population sciences and policy
and as a professor of prevention
and community health at the Milken
Institute School of Public Health
at GW.
Berg is a clinical psychologist with
research expertise in multilevel determinants of health, with an emphasis on high-risk populations such as
young adults, racial minorities, and
the LGBTQI population. She is a recognized expert on the implementation of tobacco control policies and
health disparities, and has published
nearly 200 peer-reviewed scientific
reports and papers.

Berg most recently served as an
associate professor in the Department of Behavioral Sciences and
Health Education at the Rollins School
of Public Health at Emory University
and the associate director for population sciences at Emory University’s
Winship Cancer Institute.
Berg has contributed significantly
to research focused on reducing
the global toll of tobacco, the use of
which is among the world’s leading
preventable causes of death, killing
more than 7 million people worldwide every year.
“Cancer
prevention
through
population-level approaches is a
critical pillar of our work here at
the GW Cancer Center,” said Eduardo M. Sotomayor, MD, Dr. Cyrus

Katzen Family Director of the GW
Cancer
Center
and
professor
of medicine at the GW School of Medicine and Health Sciences. “Dr. Berg’s
impressive experience and track
record of community-engaged research make her a valuable addition
to our team as we continue to invest
in cancer prevention and strengthen
our partnerships in public health.”
Berg earned her PhD in clinical
health psychology from the University of Kansas. She completed residency training at Massachusetts General
Hospital/Harvard Medical School in
behavioral medicine and completed
postdoctoral training at the University of Minnesota. She received her
MBA from the Goizueta Business
School at Emory University.
“I look forward to working alongside my colleagues at GW to truly
make a difference in cancer prevention and control, and in public health
more broadly, globally, and in our immediate community,” Berg said. n

“Dr. Berg’s impressive
experience and track
record of communityengaged research
make her a valuable
addition to our team.”
EDUARDO M. SOTOMAYOR, MD

The George Washington University Cancer Center
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NEW DIRECTOR
Eduardo M. Sotomayor,
MD, (left) is the inaugural Dr. Cyrus Katzen
Family Director.

Eduardo M. Sotomayor, MD,
Installed as Inaugural Dr. Cyrus
Katzen Family Director

“I am truly honored and humbled to serve as the
inaugural Dr. Cyrus Katzen Family Director of the
George Washington University Cancer Center.”
EDUARDO M. SOTOMAYOR, MD
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With his formal installation as the inaugural Dr. Cyrus Katzen Family Director of the
George Washington University (GW) Cancer
Center on Aug. 13, Eduardo M. Sotomayor, MD,
joined an elite group of 29 endowed professors,
chairs, and directors throughout the GW School
of Medicine and Health Sciences (SMHS).
“I am truly honored and humbled to serve as
the inaugural Dr. Cyrus Katzen Family Director of
the George Washington University Cancer Center,” Sotomayor said. The recognition, he added,
“is an acknowledgment of the many people who
influenced and guided me along an exciting journey that took a boy from a small town along the
coast of Peru to America, the greatest country,
which adopted me and allowed me to fulfill my
personal and professional dreams.”
Sotomayor, a research leader in the study of
immunotherapy of B-cell malignancies, came to
GW just four years ago to serve as the director
of the GW Cancer Center. In those four years,
Sotomayor has unified GW’s cancer research
and clinical care, advancing research innovation,
personalizing cancer care, and supporting cancer policy development. His overarching goal for
the GW Cancer Center is to earn designation as
a National Cancer Institute (NCI) comprehensive
cancer center.
“We know we got the right person for the job,”
said Jeffrey S. Akman, MD ’81, RESD ’85, former
vice president for health affairs, Walter A. Bloedorn Professor of Administrative Medicine, and
dean of SMHS. “We were looking for someone
with big ideas who could build a cancer center.”
The search committee, he said, was particularly
impressed with Sotomayor’s “vision, passion,
deep knowledge of NCI cancer centers, and desire to build something from the ground up.”
The installation ceremony featured a cavalcade of honored guests, including members of
the Katzen and Sotomayor families, the Cyrus
Katzen Foundation board, current and former
GW presidents, and senior leadership representing the university’s health enterprise. Robert C.
Gallo, MD, a longtime mentor of Sotomayor who
is best known for his role in the discovery of HIV
and the development of the HIV blood test, was
also on hand for the event.
“Today is a significant day for my entire family,”
said Jay Katzen, MD ’72, BA ’67. The two-time GW

alumnus and director of the Cyrus Katzen Foundation recalled his family’s extensive ties to GW
and the impact cancer has had on his family.
“We’re here to continue to build upon the
important legacy my father, Dr. Cy Katzen, has
established here at GW and in the Washington,
D.C., region in the area of cancer research and
patient-related cancer care,” said Katzen, who is a
member of the SMHS Dean’s Council, a member
of the Katzen Cancer Research Center Board of
Directors, and a former member of GW’s Board
of Trustees, serving from 2010 to 2018.
The Katzen family’s support over the past
two decades has been critical to cancer care at
GW and in Washington, D.C. In 2008, Cyrus and
Myrtle Katzen made a $10 million gift to establish the Dr. Cyrus and Myrtle Katzen Cancer
Research Center.
“Dad made this gift because he knew that
funding research is the only way to find a cure,”
recalled Katzen. “He saw potential in GW, and he
knew that under the right leadership GW could
have a premier cancer center someday.”
Since then, the Katzen Center has served as
the medical home for thousands of people in
their most vulnerable times as they go through
treatment.
“Endowed gifts such as this are the cornerstone of philanthropy,” said GW President Thomas LeBlanc. “The earnings they generate enrich
and sustain our work across the university, reaching all corners of the campus, in perpetuity.”
The gift of an endowed directorship will support the GW Cancer Center by enhancing basic
science and translational research and funding
new treatment protocols, academic needs for
medical students and clinicians, honoraria for visiting scholars, pilot research grants for residents
and fellows, and equipment needs.
Cyrus Katzen’s legacy, Sotomayor added, “is
one of compassion for patients and their families
during the life-altering aftermath of cancer diagnosis. He and his family lived through this journey, and they are empathetic partners who share
our commitment to creating a cancer-free world.
“Each one of us in this room plays an important role in the fight against this terrible disease.
I look forward to the journey ahead together
as we continue to fulfill the proud legacy of the
Katzen family.” n

Lemon Aid
A recent visit to the George Washington
University (GW), and the school’s 500,000
square-foot Science and Engineering Hall, left
Sebastian (then 8) and Luca (then 6) Stafford
impressed by the volume of research happening
at the university. The brothers were particularly
impressed by the high-resolution cancer
microscopy images decorating the GW Cancer
Center’s 8th floor lobby. Inspired, the two set up
a lemonade fundraiser to help support the GW
Cancer Center.

The George Washington University Cancer Center
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BIO BANKING
MAJOR NIH GRANT SUSTAINS THE LARGEST
HIV MALIGNANCY SPECIMEN BANK
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BIOREPOSITORY FOR
DOMESTIC TRIALS
The AIDS and Cancer Specimen
Resource, the largest collection
of annotated HIV malignancy
specimens globally available
to researchers, has received
renewed grant funding, with the
George Washington University
serving as the primary site for
the next five years. Sylvia Silver,
DA, will serve as the director of
the AIDS Malignancy Clinical Trials Consortium Biorepositories.

BY ASHLEY RIZZARDO

HIV/AIDS currently affects more than 35
million people worldwide. Infection with HIV is
associated with a wide range of long-term health
complications, including the development of
cancer, which is a major cause of death among
individuals living with HIV. The AIDS and Cancer
Specimen Resource (ACSR), the largest collection
of annotated HIV malignancy specimens globally
available to researchers, has received renewed
grant funding, with the George Washington University (GW) serving as the primary site for the
next five years. The renewal includes a $22 million
grant from the National Institutes of Health.
The ACSR was established in 1994 through a
cooperative agreement with the National Cancer
Institute (NCI) and is overseen by principal investigators from the two legacy sites, GW and the
University of California, San Francisco. The ACSR
also includes consortia at Baylor Medical College;
Mayo Clinic in Scottsdale, Arizona; and Stellenbosch University in Cape Town, South Africa.
“Through this grant, we are working to acquire,
store, and equitably distribute tumor tissues and
biological fluids from individuals with HIV-associated malignancies to meet the biospecimen
needs of researchers studying HIV-associated
malignancies,” said Sylvia Silver, DA, director of
the GW Biorepository and professor of microbiology, immunology, and tropical medicine at the
GW School of Medicine and Health Sciences.
As part of the award, Silver, one of the principal investigators on the project, will serve as the
director of the AIDS Malignancy Clinical Trials

Consortium (AMC) Biorepositories. The AMC,
which is funded by the NCI, engages more than
250 clinicians and conducts clinical trials in the
United States, sub-Saharan Africa, and Latin
America. Currently, the AMC biorepositories are
located at GW for U.S. domestic trials and at Stellenbosch University for African trials.
During the grant cycle, Silver will assist NCI in
the selection of a new ACSR site in Latin America
to support AMC clinical trials in the region. In
early 2014, Silver worked closely with her South
African counterparts to provide quality management expertise and advice on best practices as
Stellenbosch University prepared to launch the
sub-Saharan African biorepository.
The GW Biorepository has served as a comprehensive, state-of-the-art resource for biospecimen processing, storage, and disbursement,
designed to help today’s leading investigators
facilitate their research. In 2019, the GW Biorepository earned designation as a core facility and
accreditation by the College of American Pathologists.
The GW Biorepository is one of seven core facilities — along with the Biostatistics Center, Flow
Cytometry Core Facility, GW Biomarker Discovery and Analysis Core Facility, McCormick Genomic and Proteomic Center, Nanofabrication
and Imaging Center, and the Research Pathology
Core Labs. These facilities offer a range of services, including cutting-edge technologies and
high-end instrumentation coupled with research
technical support for university investigators. n

The George Washington University Cancer Center
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MAMMOVAN
in the Making

In 1995, the Prevent Cancer Foundation, a Washington, D.C., nonprofit,
conducted a needs assessment of the community and determined that
the District had many gaps in access to mammography services.
The foundation chose the George Washington University (GW)
to help close those gaps with its mobile mammography program.
From that original partnership, as well as with new relationships
including the Eagle Bank Foundation, GW’s Mammovan has been
providing mammography services throughout the metropolitan
area for nearly 25 years. That support has increased access to
mammography services for nearly 2,000 women annually.

GOAL

To make lifesaving
early detection of breast
cancer possible for all women
throughout metropolitan
Washington, regardless of
their ability to pay

BY THE NUMBERS
Length: 39 feet
Weight: 14 tons38 women screened in 2018
708 women screened in 2019, as of August
397 of those screened were uninsured Latinas
Almost 40,000 women screened since Mammovan’s inception
70 partnerships with local organizations
Mammovan can screen 25 patients a day
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MORE INFORMATION
To learn more about the GW Mammovan
and to support its mission of curable,
treatable breast cancer for all women,
visit www.supportthemammovan.org.

ANNUAL EVENT SUPPORTS
GW CANCER CENTER’S
COMMITMENT TO EARLY DETECTION
INSIDE THE VAN
> The GW Mammovan is a selfcontained, customized mobile
breast imaging clinic bringing
digital technology with 3D mammograms conveniently to local women within minutes.
> It is both handicapped- and
wheelchair-accessible.
> It has the most comprehensive
mammography system available
today — Genius 3D mammography
technology with the Hologic Selenia
Dimensions Mammography System.
> The van is spacious, warm, and
inviting, featuring three climate
zones and individual changing rooms with private waiting
areas for maximum comfort.

The George Washington University (GW) Cancer Center rolled
out the pink carpet for the 8th Annual GW Blush Luncheon at the
Ritz-Carlton in Washington, D.C.,
to benefit the GW Mammovan.
Robert Kelly, MD, former CEO
of the GW Medical Faculty Associates, and Jeffrey S. Akman, MD ’81,
RESD ’85, former vice president for
health affairs, Walter A. Bloedorn
Professor of Administrative Medicine, and dean of the GW School
of Medicine and Health Sciences,
welcomed the 200-plus attendees
on hand for the event. Kelly lauded
the role the Mammovan plays in the
community, providing access to
critical mammography services, encouraging early detection of breast
cancer by screening women where
they live and work, and scheduling
follow-up services for those who receive suspicious findings.
“We celebrate the survivors in
the room,” Akman told the attendees. “It is our honor to have you
here with us today. We are committed to supporting you as you continue on your journey to wellness.
“This occasion also allows us to
shine a light on the innovative and
novel research that is taking place in
the labs and in the clinics. At GW, our
researchers are directly responding
to the needs of our community.”
The annual luncheon highlighted survivor stories as well as an onsite text-to-donate campaign and a
silent auction. NBC4 anchorwoman Eun Yang again presided over
the event and offered a special
tribute in honor of journalist Cokie
Roberts, a longtime supporter of
the Blush Luncheon, who died in
September 2019 following her 17year battle with breast cancer.

The 2019 Community Service
award was presented to breast cancer survivor Marie Sylla-Dixon, vice
president of T-Mobile, for her longstanding support for the Mammovan. D.C. City Councilmember Vincent Gray presented proclamations
from the Mayor’s Office and the City
Council in honor of the occasion.
Nicole Quiroga, CEO of the Greater Washington Hispanic Chamber of
Commerce, served as the featured
speaker at the luncheon in conversation with Washington Business
Journal Vice President James MacGregor. Quiroga drew attention to
the plight of Hispanic women, who
typically are diagnosed in the later
stages of the disease often due to
a lack of access. She urged women
to take advantage of all of the resources at their disposal, such as the
Mammovan, that screen regardless
of insurance status.
The event — which featured major sponsors including McKesson
Corporation, GW Hospital, GW
Medical Faculty Associates, and
T-Mobile, as well as continued support from the Safeway Foundation
and nearly 30 additional sponsors
and in-kind supporters — raised
more than $200,000 for 2019. All
of the proceeds go directly to support the operational expenses of
the Mammovan.

The George Washington University Cancer Center
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DELVING INTO DATA
GW CANCER CENTER RESEARCHER EXPLORES
THE IMPACT OF HEALTH POLICY ON PATIENT CARE

BY CAROLINE TRENT-GURBUZ

H

umans, by nature, are complex; they’re sometimes puzzles to be studied and solved. On
paper, they can be divided and classified, neatly sifted into categories based on codes
and diagnoses and demographics; this makes them more decipherable, but no less fascinating. For Lorens Helmchen, PhD, a scholar who speaks enthusiastically of his research,
that deep dive into data and the resulting percentages and probabilities provide insight
into three parties in health care: patient, provider, and insurer.
Helmchen’s study, “The Impact of Greater Reimbursement for Chemotherapy Drugs
on Cancer Care Among DC Medicaid Enrollees,” focuses primarily on the effect of a 2016
Medicaid policy that increased the reimbursement of physician-administered chemotherapy drugs to 100% from 80% of the Medicare fee schedule. The initial funding for
the study came from the Cyrus and Myrtle Katzen Cancer Research Center’s Catchment
Area Pilot Awards, which are intended to promote research that improve cancer health
outcomes for individuals in the Washington, D.C., area.
“What we wanted to do was understand how did care change in the aftermath of this
policy change,” explains Helmchen, associate professor of health policy and management at the Milken Institute School of Public Health at the George Washington University
(GW) and a member of the GW Cancer Center.
The preliminary takeaways of this study on the reimbursement change are intriguing:
providers may increase the frequency of diagnostic testing and aggressive treatment,
patients may see more health care providers, and financial incentives from insurers can
be powerful motivators.
Helmchen cautions that he cannot attribute these changes unambiguously to the
policy change because the study was descriptive; he looked solely at medical claims of
patients who were covered by Medicaid and thus were all exposed to the policy change.
The claims contained patient demographic information — age, gender, race, and place of
residence — as well as diagnostic and procedural codes. He studied approximately 2,100
Medicaid enrollees whose medical claims recorded a diagnosis of prostate cancer and

The George Washington University Cancer Center
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After a 2016 Medicaid policy increased the
reimbursement of physician-administered
chemotherapy drugs, prostate cancer patients
in the Medicaid program were about a third
more likely to receive treatment than before.

approximately 2,600 Medicaid enrollees whose
medical claims included a breast cancer diagnosis between 2013 and 2017. “We [then] used the
claims to characterize what happened after the
policy had gone into effect,” he says. “So, what
did we find?”
One of the “most salient findings,” he says, was
on the treatment arc for prostate cancer patients
diagnosed within the aforementioned five-year
range. “We detected an increase in the probability that they would receive a CT scan or an
MRI scan or a bone scan of about 7.5 percentage
points, so that’s fairly significant.”
He also focused on whether these patients received any of three types of treatments: chemotherapy, radiation, or surgery. “After the policy
had been implemented in 2016, prostate cancer
patients in the Medicaid program were about a
third more likely to receive treatment than before,” he says.
There was, however, one unexpected finding.
Helmchen expected patients to receive chemotherapy more often than before the policy change
because its reimbursement had increased. Early
results indicate otherwise; there was no statistically significant increase in the use of chemotherapy, or radiation and surgery. (Breast cancer
patients, as a whole, did not see a statistically significant change in treatment patterns at all.)
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He notes that the lack of such a change in
treatment patterns “gives a lot of credit to the
providers. Financial inducements failed to bring
about a detectable change in the treatment patterns [for breast and prostate cancer patients],
other than raising the probability of CT and MRI
scans for prostate cancer patients and raising the
overall treatment for prostate cancer patients.”
So, what does that mean? The policy change
could have appealed to providers to continue
treating prostate and breast cancers with the
same number of chemotherapy agents, rather
than expanding the treatment plan to include
potentially more chemotherapy or the additional
invasive options of surgery plus radiation.
“If [treating patients with chemotherapy
agents] is financially attractive for providers, then
providers have an incentive to encourage greater
rates of diagnosis, so that would be consistent
with our finding that the probability of receiving
a CT or MRI scan increased,” Helmchen explains.
“And … you’re bound to find more cancers if you
increase the diagnostic effort.”
“If you make it more attractive to provide
chemotherapy treatment, you make it more attractive for additional providers to see patients,
so perhaps it’s not too surprising that patients
would see more providers because they have
more choice now,” Helmchen concludes. n

“Perhaps it’s not too surprising that
patients would see more providers
because they have more choice now.”
LORENS HELMCHEN, PhD
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cancers. His team is particularly interested in
the tissue specificity and
why women who carry
BRCA1 mutations have a
particularly high risk for
developing breast and
ovarian cancer.
While at the Mays
Cancer Center, Li saw
the opportunity to interact with clinicianscientists and began
connecting with breast
oncologists and surgical oncologists to build
a cross-disciplinary breast cancer research team.
Li hoped to compare the breast tissue of BRCA1-mutation-carrying women with tissue from
non-carriers to possibly identify an early signature indicating what is unique about breast tissue and what really happens at the early stage
of breast cancer development in women who
carry the mutation. To do that, Li and his crossdisciplinary team of oncologists and plastic
surgeons built a collection of patient samples.
From there, the team worked with genomic analysts to find signatures that occur only in BRCA1
mutation carriers.
“In my career, I’ve found that discoveries in science often lead you to unexpected territory,” says
Li, who recently began a project on tumor immunology in his GW Cancer Center lab. It’s an area
he says he still finds fairly daunting. However, in
such areas he finds the opportunity to connect

BUILDING A CROSSDISCIPLINARY NETWORK
Rong Li, PhD, joined
the George Washington
University (GW) School of
Medicine and Health Sciences in 2018. He recently
began a project on tumor
immunology in his GW
Cancer Center lab, which
has provided him with the
opportunity to connect
with clinician-scientists
and researchers in other
basic science departments.

Cross-Disciplinary
Cancer Research
When Rong Li, PhD, arrived at the George
Washington University (GW) School of Medicine
and Health Sciences (SMHS) in 2018 from the
University of Texas Health Science Center at San
Antonio, he was enthusiastic at the prospect of
becoming a member of the GW Cancer Center.
“There are several things that excited me
about GW and the GW Cancer Center,” says Li,
the Ross Professor of Basic Science Research
and chair of the Department of Biochemistry and
Molecular Medicine at SMHS. “There are a lot of
exciting new initiatives here … In my experience
here so far, I see a lot of potential for cross-disciplinary actions.”
Prior to joining GW, Li — a molecular biologist
focused on the fundamental aspects of cancer
biology, particularly how cells duplicate and how
they acquire mutations — served as a co-leader
for the Cancer Development and Progression
Program at the Mays Cancer Center, a National
Cancer Institute-designated cancer therapy and
research center.
Li also leads ongoing research into the tumor
suppressor gene BRCA1, a gene connected to risk
for certain cancers, including breast and ovarian

“In my career, I’ve found that
discoveries in science often lead
you to unexpected territory.”
RONG LI, PhD

with clinician-scientists and researchers in other
basic science departments, such as bioengineering and microbiology, immunology, and tropical
medicine, to brainstorm the direction of research.
“Our research benefits tremendously from this
kind of cross-disciplinary network,” Li says. n

The George Washington University Cancer Center
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How to Spell Quality Care Using

L G B T Q I
WORKING WITH A DIVERSE COMMUNITY IS HELPING THE GW CANCER
CENTER DEVELOP RESEARCH INNOVATIONS AND CLINICAL CARE FOR ALL
BY KATHERINE DVORAK

A
LISTENING TO
THE COMMUNITY
Washington, D.C., has
among the highest percentage of individuals
who identify as lesbian,
gay, bisexual, transgender, queer, or intersex.
The staff at the George
Washington University
Cancer Center ensures
the city’s residents
are always heard.

t the George Washington University (GW) Cancer Center, listening to the needs of
the community is a vital responsibility. That’s why in the city that has among the highest percentages of individuals who identify as lesbian, gay, bisexual, transgender,
queer, or intersex (LGBTQI), the GW Cancer Center is ensuring its residents are always heard.
“It’s important that the people you are trying to serve are guiding your priorities.
Otherwise you’re not doing your job; you’re not meeting their needs,” says Mandi L.
Pratt-Chapman, PhD, associate center director for patient-centered initiatives and
health equity at the GW Cancer Center.
One of the ways the center is filling seats at the table is through the LGBTQI Research Community Advisory Board, or CAB, which comprises more than a dozen representatives from the metro Washington, D.C., community and local organizations.
Rachelle Tepel, PhD, community member and former chair of the board, says its
mission is “to connect health care researchers, specifically in the cancer fields, to
the LGBTQI community in the D.C. metro area.” The board helps forge important
connections between researchers and the community.
In July 2018, the GW Cancer Center, in partnership with health care workers,
community members, researchers, and D.C. organizations, set the stage for the
CAB’s work. The center hosted a one-day workshop to facilitate conversations on
the health needs of the LGBTQI community. From the event emerged top research
priorities, such as finding solutions for social isolation among transgender women
and LGBTQI elders, and increasing provision of culturally responsive care for patients, among others.
Tepel, a member of the LGBTQI community and a cancer survivor, notes that
in addition to identifying research priorities, education of providers on how to be
more inclusive is important to the CAB and to her personally.

The George Washington University Cancer Center
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“It’s important that the people
you are trying to serve are
guiding your priorities. Otherwise
you’re not doing your job; you’re
not meeting their needs.”
MANDI L. PRATT-CHAPMAN, PhD

“Because of my experience with health care
providers in the past, it’s important to me to try to
get the health care providers to be more aware of
the needs of the community,” she says.
A year later, the CAB participated in a networking event during which researchers at GW and
other universities in the area presented the projects they were working on to community members. “Sometimes it feels like we’re asking community members what they need over and over
again, but not showing them evidence of what
we’re doing to try to answer some of those needs.
We wanted to shift that,” says Pratt-Chapman.

Embracing Lived Experiences
Eduardo M. Sotomayor, MD, Dr. Cyrus Katzen
Family Director of the GW Cancer Center and
professor of medicine at the GW School of Medicine and Health Sciences (SMHS), adds that a city
that ranks high in overall cancer mortality must
provide equitable care for all. “We want everyone
who walks in the door to feel empowered, [be]
engaged, and have ownership over their care,”
Sotomayor says.
Relationship and trust building in the LGBTQI
community is paramount, and something on
which the GW Cancer Center is focused.
“There are huge differences among the L, the
G, the B, the T, the Q, and the I,” Pratt-Chapman
says. Even within the community, she adds, it’s a
constant process of learning, building trust, and
making sure CAB members are focusing on the
right things. “We need to think about how sex
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and gender identity
SEXUAL AND GENDER
MINORITY TRAINING
and transgender lived
Mandi L. Pratt-Chapman,
experiences
affect
PhD, envisions the creation of
health and how intersexual and gender minority
ventions work.”
training for cancer centers
Prat t- Chapman
across the United States, with
says that technical asthe GW Cancer Center at the
sistance and training
forefront of the movement.
provided by her team
emphasize that each
person has a unique lived experience. She envisions the creation of sexual and gender minority
training for cancer centers across the United States,
with the GW Cancer Center at the forefront of the
movement.

Open Trials
Clinical trials are key to research, and making trials open to members of the LGBTQI community
and ensuring they feel comfortable participating
is top of mind in the GW Cancer Center Clinical
Trials Office.
“We want to make all patients feel comfortable, feel free to talk with us about any concerns,
and be open to receive them and give them
equal opportunity in clinical trials,” says Monica
Rengifo-Pardo, MD, a clinical research coordinator at the GW Cancer Center.
Richard Lush, PhD, director of the Clinical Trials Office, adds that there’s no specific outreach
to the LGBTQI community for trials right now, but
adds that he wants to make sure that the patients
enrolled in trials are diverse.

Currently in the works is the development of a
software system to manage the clinical trials process, Lush explains. “We want to ensure that we
are capturing data about the LGBTQI community
and how good we are at enrolling them in clinical
trials. We want to see those data,” he says.

Building Bridges
The GW Cancer Center is not an island, and
it relies on support from SMHS, Milken Institute School of Public Health at GW (Milken Institute SPH), the GW Medical Faculty Associates, and GW Hospital to further its community
outreach goals.
“The solutions to most health issues are in the
space where our different disciplines meet,” says
Carlos Rodriguez-Diaz, PhD, MPH, associate professor in the Department of Prevention and Community Health at Milken Institute SPH. “We have
to work from the simplest point, the cell, all the
way to the policies that create disparities.”
Rodriguez-Diaz is a community health scientist by both training and passion, he says. “I serve
as an adviser to the community. I’m a scientist, I
conduct research, but I am not the kind of scientist who tells the community what they need and
what research we have to do,” says RodriguezDiaz. “I like to work with the community in [such]
a way that we come up together with the kind of
research we need.”

For the past five years, Rodriguez-Diaz, who
calls Puerto Rico home, has focused primarily on sexual minorities — gay, lesbian, bisexual,
transgender, and queer populations, as well as
on Latin communities. Although his work is not
always cancer-specific, he’s connected with PrattChapman during the time he’s been at GW to
learn more about the LGBTQI community in D.C.
Since his arrival, Rodriguez-Diaz has become a
regular at CAB meetings, and he is working with
other colleagues at Milken Institute SPH and DC
Health on an HIV behavioral study with transgender women.
Rodriguez-Diaz adds that comprehensive understanding of the population rather than the disease
itself “is key to solving the health disparities we see.”
Education and knowledge also must extend
to students. Pratt-Chapman says she’s working
with other important LGBTQI leaders at SMHS, including Amy Caggiula, MD, assistant professor of
emergency medicine, and Charles Samenow, MD,
MPH, associate professor of psychiatry and behavioral sciences, on ideas for mandatory and elective sessions to help medical students think about
implicit bias and modeling affirming behaviors.
“Understanding the needs of marginalized
communities and meeting them where they are:
these are things all health professionals, including medical students, need to think about and be
taught,” she says.

Online Enlightenment
he GW Cancer Center offers evidence-based training and educational opportunities for health care professionals, patients, researchers, policymakers, and
advocates, as well as others interested in cancer-related topics. The center’s
online academy offers eight self-paced, no-cost courses on relevant topics for
health care professionals, comprehensive cancer control programs, and others.
Among the online offerings is Addressing the Need for LGBTQI-Affirming Cancer Care:
A Focus on Sexual and Gender Minority Prostate Cancer Survivors. The course helps social workers and other health care professionals support sexual and gender minority cancer patients.
For more information about this and other GW Cancer Center training opportunities,
visit gwccacademy.org.
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Pratt-Chapman Receives
$4.125 Million to Continue
Technical Assistance to
Cancer Control Programs
The George Washington University (GW)

“CDC’s renewal of our work demonstrates the
high value placed on our tailored, multilevel
strategies to advance cancer control and
reduce health inequities across the nation.”
MANDI L. PRATT-CHAPMAN, PhD
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Cancer Center is continuing its work with the
Centers for Disease Control and Prevention
(CDC) by providing technical assistance for National Comprehensive Cancer Control Program
(NCCCP) grantees through a cooperative agreement in excess of $4 million awarded to Mandi L.
Pratt-Chapman, PhD, associate center director
for patient-centered initiatives and health equity
at the GW Cancer Center.
The new five-year award is a competitive renewal of the successful $2.1 million award from
2013 to 2018. The cooperative agreement expands technical assistance efforts by leveraging the existing infrastructure, capacity, and
relationships of the talent at the GW Cancer
Center’s Institute for Patient-Centered Initiatives and Health Equity to provide support to
the grantees.
NCCCP grantees create stakeholder-driven
plans aimed at reducing the burden of cancer
through evidence-based cancer control interventions adapted to local settings, this includes
efforts to advance access to screening, treatment, and cancer survivorship care and to reduce health inequities.
“CDC’s renewal of our work demonstrates the
high value placed on our tailored, multilevel strategies to advance cancer control and reduce health
inequities across the nation,” says Pratt-Chapman.
“We look forward to another strong half decade
with this exciting and rewarding project.”

Providing Resources for Smoking Cessation
Smoking is the leading preventable cause
of death in the United States. Despite reports
from the Centers for Disease Control and Prevention of a 20% decline in smoking between 2005
and 2016, smoking rates among public housing
residents remain more than twice as high as the
national average. Cancer-related diseases, says
Lorien Abroms, ScD, follow that same pattern.
Abroms, a professor of prevention and community health at Milken Institute School of Public
Health (Milken Institute SPH) at the George Washington University (GW), created a pilot program
for Washington, D.C., public housing residents
who were interested in quitting smoking. She explains, “addressing the disparities is really important for reducing cancer.”
In August 2018, the U.S. Department of Housing and Urban Development (HUD) issued a national ban on smoking in all public housing facilities. When HUD passed the rule, many facilities
were left without the resources to help their residents make the adjustment.
The reasons for the ban on smoking are threefold, says Debra Bernat, PhD, associate professor
of epidemiology and biostatistics at the Milken
Institute SPH.
The first goal is to improve the health of residents, the second is to reduce fires, and the third
is to reduce maintenance costs. Bernat is currently leading a study, funded by a grant from the
National Institutes of Health, to understand how
the rule affects smoking behavior and second-

hand smoke exposure
among public housing
residents. She has also
partnered with Abroms
— who is the founding director of the GW
mHealth Collaborative
and a member of the
GW Cancer Center —
for the pilot, which is
funded by the Milken
HELPING HOUSING
Institute SPH Research
RESIDENTS QUIT
Innovation Award.
Lorien Abroms, ScD, created
a pilot program for Wash“Many of the resiington, D.C., public housing
dents in public housresidents who were intering have been smoking
ested in quitting smoking.
cigarettes for decades,”
Bernat explains. “Despite this, many are interested in quitting.”
In 2008, Abroms developed Text2Quit, a text
messaging smoking cessation program, which is
now offered through the American Cancer Society/Optum Quit For Life program. The team
plans to test a version of the program adapted to
the context of D.C. public housing, which sends
text messages motivating people to quit smoking
— an intervention tactic that has become increasingly common in behavioral change efforts such
as smoking cessation. In addition to Text2Quit,
residents will have access to Text4Coach, a text
messaging program that links smokers to proactive quitline counseling.
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COMPLEMENTING
PATIENT CARE
Christine Teal, MD, director of the GW Breast Care
Center and the chief of
breast surgery, looks for
new ways to complement patient care. Photo
by Susan Gendron.

The Art of Giving
AT THE GW BREAST CARE CENTER,
FUNDRAISERS AND DONATIONS UPLIFT PATIENT CARE
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BY KATHERINE DVORAK

A

diagnosis of breast cancer is
a scary moment in any person’s life, and going through
treatment can be difficult on
both the mind and the body,
but at the George Washington University (GW) Cancer
Center, the journey can be made a little easier
thanks to support from current and former patients and community members.
Through a patient and community membersupported patient assistance fund, the GW
Breast Care Center is able to offer financial
assistance and a monthly complementary care
clinic for patients. The fund was started in 2007
by GW patient LuAnn Dean.
Some of the money that goes into the fund is
collected during a fundraiser often held in the
fall. The fundraiser has looked different over the
years; such as silent auctions or golf tournaments.
“The fundraiser and patient assistance fund
have really enabled us to help our patients both
financially and through a holistic care program,”
says Christine Teal, MD, director of the GW Breast
Care Center and the chief of breast surgery.
Financial support can include helping
patients pay their rent or providing them with
transportation options, she says.
Then there’s the complementary clinic, which
Teal says the patients love. It’s offered once a
month and is supported by providers from the
GW Center for Integrative Medicine. During the
clinics, patients have the opportunity to sample a
variety of complementary medicine options. They
can meet with a naturopath, who can discuss with
them natural approaches to cancer treatment, as
well as provide advice on what supplements may
help ease pain and offer nutritional counseling.
Patients may also receive acupuncture therapy
to help relieve nausea from chemotherapy; the

WITH PATIENT AND
COMMUNITY SUPPORT
Christine Teal, MD, says
a patient and community member-supported
patient assistance fund
makes the GW Breast
Care Center unique in
what it can provide for
patients. The fund was
started in 2007 by GW
patient LuAnn Dean.

centuries-old medicine uses hair-thin needles to
stimulate points along the nervous system.
Another specialty available during the clinic
is reiki, a healing technique in which a therapist
channels energy into the patient through touch
to activate the natural healing processes of the
patient’s body and restore well-being.
“These offerings allow us to make the GW
Breast Care Center a little more unique in what
we can provide for patients,” says Teal. “And it’s
a special bonus because insurance won’t cover
these complementary therapies.”
In addition, the center uses the fund to have a
physical therapist visit the clinic two afternoons a
month. “Some of our patients, such as those who
have had bilateral mastectomies with reconstruction, need stretching or more work, and through
this they can be seen more than once a month
when they are also seeing their surgeon,” Teal says.
The fund isn’t supported just by the annual fundraiser, but also by current and former patients who
want to give back. Teal says letters are sent out to
patients who have experienced the complementary clinic to see if they would be willing to support
it. “We often have a very nice response,” Teal notes.
Teal also has held fundraising campaigns herself, including one two years ago in honor of her
mother, who had breast surgery done at GW.
“When the patients and community see how near
and dear it is to me to provide these programs,
they see the importance of it,” she says.
She adds that seeing current patients and former patients give back, including those who have
been giving for many years, is heartening. “It
doesn’t have to be a big donation. Just that they
are willing to give is meaningful,” she says.

The George Washington University Cancer Center

23

SUPPORT GROUPS
The George Washington University Cancer Center, with support provided by the Dr. Cyrus and Myrtle
Katzen Cancer Research Center, supports a wide variety of holistic and wellness services for cancer
patients and their families. These groups are free of charge and open to the community.

THE GW MEDICAL
FACULTY ASSOCIATES (MFA)
2150 Pennsylvania Ave., NW
Washington, D.C. 20037

ALL CANCERS
Open to all cancer patients currently in
treatment. Registration required.
Second and fourth Wednesday of each
month, 12:30–1:30 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-677-6229
CAREGIVER SUPPORT GROUP
Open to caregivers of those diagnosed
with cancer to share common concerns,
give and receive advice, and learn
coping skills. Registration required.
Third Tuesday of each month
12:30–1:30 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582
GENTLE YOGA
This group introduces patients
and caregivers to the physical and
emotional benefits of yoga.
Tuesdays, 4–5 p.m.
GW Marvin Center,
fifth floor activities room
800 21st St., NW
Facilitator: Yael Flusberg
dgarcia@mfa.gwu.edu
202-741-2582

HEAD AND NECK CANCER GROUP
For head and neck cancer patients
and survivors, and their caregivers.
Registration required.
First Tuesday of each month
12:30–1:30 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582

PROSTATE CANCER GROUP
The prostate cancer education group
is open to patients and survivors, and
their caregivers. Registration required.
Second Tuesday of each month
6–7 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582

METASTATIC BREAST
CANCER SUPPORT GROUP
This group is open to metastatic breast
cancer patients. Registration required.
Fourth Tuesday of each month
Noon–1 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582

SURVIVORSHIP SERIES
An educational series featuring a
different speaker each month.
Second Thursday of each month
11:45 a.m.–12:45 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582

MULTIPLE MYELOMA GROUP
This group is open to multiple
myeloma patients and survivors, and
their caregivers. Registration required.
Third Tuesday of each month
5:30–6:30 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582
NUTRITION CLUB
This group is open to patients and
survivors, and their caregivers.
Registration required.
First Monday of each month
Noon–1 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Jennifer Leon
jleon@mfa.gwu.edu
202-741-6489

YOUNG ADULT GROUP
Young adults (19–39 years of age) who
are currently in treatment or are cancer
survivors.
Third Sunday of each month
5–6:30 p.m.
Smith Center for Healing and the Arts
1632 U St., NW
Facilitator: Jennifer Bires, LiCSW, OSW
202-483-8600
Parking is validated for all groups
at the GW Cancer Center. For
more information about upcoming
support groups and events, visit

cancercenter.gwu.edu/for-patients/
patientcaregiver-support.

External
Advisory Board
Edward J. Benz Jr., MD
President and CEO Emeritus,
Dana-Farber Cancer Institute
William Dalton, MD, PhD
founder and CEO, M2Gen, former
director, Moffitt Cancer Center
Timothy J. Eberlein, MD, FACS
director and Bixby Professor
and Spencer T. and Ann W. Olin
Distinguished Professor,
Alvin J. Siteman Cancer Center;
and chair, Department of
Surgery, Washington University
School of Medicine
Bernard F. Fuemmeler, PhD, MPH
Gordon D. Ginder, MD, Chair in Cancer
Research; associate director of cancer
prevention and control; and professor,
Virginia Commonwealth University
Stanton Gerson, MD
director, Case Comprehensive
Cancer Center; director, National
Center for Regenerative Medicine;
and professor of medicine and of
environmental health sciences,
Case Western Reserve University
Helen Heslop, MD, PhD
Dan L. Duncan Chair; director, Center
for Cell and Gene Therapy; associate
director for clinical research, and
professor of pediatrics and of
medicine, Dan L. Duncan
Comprehensive Cancer Center,
Baylor College of Medicine
Victor Santana, MD
vice president for clinical trials
administration; associate director
of clinical research, Comprehensive
Cancer Center; and Charles B. Pratt
Chair in Solid Tumor Research, St
Jude Children’s Research Hospital
Marcy Waldinger, MHSA
former chief administrative officer,
University of Michigan Cancer Center
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Innovative Cancer
Treatment Made Care
Easier to Swallow
Joel Hinzman is a busy dad, husband, and lobbyist who never expected to be diagnosed with
tonsil cancer at age 46. The first sign of a problem
was swelling on the left side of his neck that got
worse and more painful, despite taking antibiotics. In seeking cancer treatment, one option that is
part of a clinical study at the George Washington
University (GW) Cancer Center stood out, based
on Hinzman’s research. “It looked like it had great
long-term outcomes and the best chance for minimum side effects over the long term,” he says.
Maintaining his quality of life was important to
him, and he wanted to enjoy eating and his sense
of taste when his treatment was done.

TO TREAT HEAD AND NECK CANCERS, GW HOSPITAL
OFFERS THE MEDROBOTICS FLEX® ROBOTIC SYSTEM.
This innovative technology is designed to navigate the body’s twists and
turns and can provide a compelling resource for treating other conditions
as well. Minimally invasive robotic surgery can reduce pain and trauma
to the body, leading to a shorter hospital stay and a quicker recovery.

Game-changing care
The type of cancer Hinzman had was associated
with the human papillomavirus (HPV). Traditionally, treatment in these cases has involved chemotherapy and radiation, says Director of Head and
Neck Oncologic and Microvascular Reconstructive Surgery Arjun Joshi, MD, FACS, FRCS(C).
However, patients in the clinical study, explains
Joshi, who also serves as professor of surgery at

GW School of MediBEST LONG-TERM OUTCOME
cine and Health SciDiagnosed with tonsil cancer
at age 46, Joel Hinzman took
ences (SMHS), and as
part in a clinical study at the
a member of the GW
George Washington UniversiCancer Center, rety Cancer Center because that
ceive chemotherapy
treatment offered the best
and then robotic suroutcome over the long term.
gery avoiding radiation and its potential
lifelong side effects, such as dry mouth, changes
in taste, dental disease, and others.
Within 48 hours of his first dose of chemotherapy, Hinzman noticed that the tumor on his neck
was significantly smaller. By the end of the third
treatment, the cancer was hard to find. He then
underwent surgery to remove what tumor remained at the tonsil and in the lymph nodes in his
neck. Pathology showed that the tumor at both
sites had disappeared. He remains cancer-free
more than two years after surgery. Also, he has no
problems with taste or swallowing, and is grateful
to have his normal oral functioning intact. “I had
great care at GW Hospital and as an outpatient,”
he says of his treatment led by Joshi and medical
oncologist Robert Siegel, MD, associate center
director for professional outreach and networks
at the GW Cancer Center.
Hinzman adds, “I appreciated the fact that I
was at a teaching hospital, with great residents
coming in and checking on me regularly.”

?

DID YOU KNOW it is estimated that about 3,400
new cases of HPV-associated oropharyngeal cancers
are diagnosed in women and about 14,800 are
diagnosed in men each year in the United States.
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